Why Ozempic And 14 Other Drugs Could Get Cheaper In 2027 | Global News Avenue

Why Ozempic And 14 Other Drugs Could Get Cheaper In 2027

Main points

• Medicare will negotiate prices for Ozempic and 14 other drugs in 2025, with prices taking effect in 2026.
• The negotiations could lower prices for Medicare beneficiaries, helping more people afford the weight-loss drug that currently costs nearly $1,000 a month.
• This is the second consecutive year that Medicare has conducted drug price negotiations, following the Inflation Reduction Act of 2022, which authorized Medicare to conduct drug price negotiations.

Blockbuster weight loss drug Ozempic could become cheaper in 2027 as it is on the government’s list of drugs targeted for price negotiations this year.

The U.S. Department of Health and Human Services said Friday that Medicare will negotiate prices with manufacturers in 2025 for 15 drugs, including the weight-loss drugs Ozempic, Weygovy and Rybelsus. The new prices will take effect in 2027.

This is the second year of the government health insurance scheme for the elderly Negotiate drug prices The Inflation Reduction Act authorizes it to do so in 2022. The first round of negotiations in 2024 resulted in price cuts for 10 drugs, which will take effect in 2026, Saving Medicare Beneficiaries Out-of-pocket costs are estimated at $1.5 billion.

The second round may be more important because it includes three drugs in the “GLP-1 inhibitor” class, which have been shown in scientific trials to be highly effective in treating obesity and diabetes but are prohibitively expensive for many beneficiaries. Intimidated.

For example, a Senate hearing earlier this year found that U.S. residents pay Ozempic $969 per month. Under a White House policy announced earlier this year, Medicare and Medicaid Diet pills will begin to be covered 2026.

Other drugs on the 2025 negotiation list include:

• Ellipta Trelegy (COPD and Asthma)
• Xtandi (prostate cancer)
• Pomalyst (cancer)
• Ibrance (breast cancer)
• Aoff (pulmonary disease)
• Linzess (Irritable Bowel Syndrome)
• Carl Koons (leukemia)
• Austedo; Austedo XR (symptoms of Huntington’s disease)
• Breo Ellipta (asthma)
• Tradjenta (diabetes)
• Xifaxan (Irritable Bowel Syndrome)
• Freral (mental illness)
• Janumet; Janumet XR (diabetes)
• Otezla (psoriasis)